5th gen glp-1 Understanding the Next-Gen Weight Loss Drug: Retatrutide (GLP-1, GIP, and Glucagon Receptor Agonist) Glucagon-like peptide 1 receptor agonists:

it is about timing and consistency

TB-500 distributes systemically, so injection site precision matters less

In the pivotal SURMOUNT-1 trial involving adults without diabetes, participants receiving the highest dose (15 mg) lost an average of 20.9% of their body weight over 72 weeks, compared to 3.1% with placebo

By prioritizing safety and evaluating long-term outcomes, researchers gain a clearer understanding of the benefits of using these peptides in advanced studies

GLP-1 receptor agonists work by activating the GLP-1 receptors, which stimulate insulin secretion and decrease glucagon release, leading to better glycemic control

If this episode was helpful, if you like hanging out with me, make sure you subscribe